The European Commission has approved Novo Nordisk’s new FlexTouch prefilled insulin pen. Approval has been granted for both NovoRapid (insulin aspart) and Levemir (insulin detemir), both modern insulins that are currently delivered in the FlexPen delivery device.
The Danish pharmaceutical firm says FlexTouch, its latest prefilled delivery system, offers a new insulin injection experience for users. Current insulin pens require users to inject their insulin using the force of their thumb to push the button. For some patients this can be difficult. FlexTouch has an easy touch button, which requires very little force to inject the insulin at any dose.
FlexTouch contains 300 units of insulin and doses in one-unit increments, from 1–80 units. It is compatible with NovoTwist needles, which are supplied in 5mm (32G Tip) and 8mm (30G) versions. An audible and tactile ‘click’ confirms attachment of the needle.
The launch of the FlexTouch in the EU is dependent on negotiations in individual countries.
Novo Nordisk gains EU approval for FlexTouch
Danish firm\'s latest innovation within prefilled insulin pens
You may also like
Trending Articles
You may also like
NHS
£70m investment in radiotherapy technology to transform cancer care across England
New generation linear accelerator machines to be installed at 28 hospitals from August, promising faster, safer, and more precise cancer treatment while helping to cut NHS waiting lists and reduce cancelled appointments
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
World Health Assembly adopts landmark pandemic agreement
Following over three years of global negotiation in response to the COVID-19 pandemic, the World Health Assembly has agreed a new international framework aimed at improving equitable access to essential health products and strengthening coordination for future pandemic preparedness and response